<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415985</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 116</org_study_id>
    <nct_id>NCT02415985</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly</brief_title>
  <official_title>A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bamrasnaradura Infectious Diseases Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the pharmacokinetics of rifabutin 150 mg once daily versus rifabutin 300 mg
      thrice weekly in combination with LPV/r 400/100mg based HAART in HIV/TB infected patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of the project is to evaluate rifabutin as a replacement for rifampicin, for
      the combined treatment of tuberculosis and HIV infection. Rifabutin represents an alternative
      to rifampicin for HIV infected patients as its half-life is longer and the enzymatic
      induction effect appears to be less important on the associated ART drugs. This phase II
      trial is to determine precisely the pharmacokinetics parameters of rifabutin in combination
      with LPV/r regimens in Thai HIV/TB infected patients, in order to define optimal doses that
      will be further tested in a larger phase III trial comparing safety, tolerability and
      efficacy of rifabutin and rifampicin regimens.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics of rifabutin Cmax</measure>
    <time_frame>48 weeks</time_frame>
    <description>Cmax The peak plasma concentration of rifabutin after administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>48 weeks</time_frame>
    <description>number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral load</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4</measure>
    <time_frame>48 weeks</time_frame>
    <description>mean CD4 rise from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monodrug resistant TB</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AIDS event</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB cure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB relapse</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidrug-resistant TB (MDR TB)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB treatment failure</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extensively drug resistant TB (XDR TB)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight gain</measure>
    <time_frame>48 weeks</time_frame>
    <description>change from baseline in weight gain at 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>defervescence</measure>
    <time_frame>48 weeks</time_frame>
    <description>change from baseline in defervescence at 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky score</measure>
    <time_frame>48 weeks</time_frame>
    <description>change from baseline in Karnofsky score at 48 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>rifabutin 150</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>rifabutin 150 mg (1 capsule) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rifabutin 300</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>rifabutin 150 mg (2 capsules) 300 mg 3 times a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/r will be supplied by NHSO/GPO</intervention_name>
    <description>200/50 mg tablet LPV/rtv</description>
    <arm_group_label>rifabutin 150</arm_group_label>
    <arm_group_label>rifabutin 300</arm_group_label>
    <other_name>LPV/rtv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <arm_group_label>rifabutin 150</arm_group_label>
    <arm_group_label>rifabutin 300</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed HIV positive after voluntary counseling and testing

          2. Aged &gt;18-60years of age

          3. PI-naïve (NNRTI intolerance/failure) or PI experience ( TB developed during on salvage
             regimen) without prior PI mutation

          4. Any CD4 cell count

          5. ALT &lt;5 times ULN

          6. Serum creatinine &lt;1.4 mg/dl

          7. Hemaglobin &gt;7 mg/L

          8. TB is diagnosed and planned to receive stable doses of rifabutin containing anti-TB
             therapy for at least another 4 week period after initiation of ART

          9. No other active OI (CDC class C event), except oral candidiasis or disseminated MAC

         10. Body weight &gt;40kg

         11. Able to provide written informed consent

        Exclusion Criteria:

          1. Current use of steroid (except short course steroid for IRIS) and other
             immunosuppressive agents.

          2. Current use of any prohibited medications related to drug pharmacokinetics.

          3. Patients with current alcohol or illicit substance use that in the opinion of the site
             Principal Investigator would conflict with any aspect of the conduct of the trial.

          4. Unlikely to be able to remain in follow-up for the protocol defined period.

          5. Patients with proven or suspected acute hepatitis. Patients with chronic viral
             hepatitis are eligible provided ALT, AST &lt; 5 x ULN.

          6. Karnofsky performance score &lt;30%

          7. TB meningitis and bone/joints ( due to longer period of anti TB drug)

          8. Pregnancy

          9. Patient choose to use efavirenz, not LPV/r. However, in ART naïve, EFV is allowed
             after intensive PK of LPV/r and rifabutin at week 2-4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIV-NAT, Thai Red Cross - AIDS Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
    <phone>662 652 3040</phone>
    <email>anchalee.a@hivnat.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chest Division, Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamol Kawkitinarong, MD</last_name>
      <email>kamonkaw@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Kamol Kawkitinarong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HIV-NAT, Thai Red Cross - AIDS Research Centre</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
      <phone>662 652 3040</phone>
      <email>anchalee.a@hivnat.org</email>
    </contact>
    <investigator>
      <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases, Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamolwan Jutivorakool, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gompol Suwanpimolkul, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Opass Putcharoen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamolwan Jutivorakool, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gompol Suwanpimolkul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bamrasnaradura Infectious Diseases Institute</name>
      <address>
        <city>Nonthaburi</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weerawat Manosuthi, MD</last_name>
      <email>drweerawat@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Weerawat Manosuthi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics of rifabutin</keyword>
  <keyword>HIV/TB co-infection</keyword>
  <keyword>resource limited setting</keyword>
  <keyword>AUC</keyword>
  <keyword>Cmax</keyword>
  <keyword>Cmin</keyword>
  <keyword>Ctrough</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

